Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STAAR Surgical Company filings document the regulatory record for a NASDAQ-listed ophthalmic device company focused on phakic IOLs and the EVO family of Implantable Collamer® Lenses. Its reports and exhibits cover operating results, preliminary sales disclosures, shareholder letters, product and market commentary, and clinical or regulatory matters tied to lens-based vision correction.
Recent filings also address proxy and governance disclosure, shareholder voting matters, board and committee composition, director independence, executive appointments and separation arrangements, material agreements, capital-structure disclosure for common stock, and the termination of a previously disclosed merger agreement.
On 18 June 2025, STAAR Surgical Company (STAA) convened its 2025 Annual Meeting of Shareholders with a strong quorum of 44,746,693 shares (≈90% of the 49.5 million outstanding).
Director elections (Proposal 1): All six nominees were re-elected for terms expiring at the 2026 meeting. Shareholder support ranged from 96%–99% of votes cast, with Arthur C. Butcher receiving 41.1 million “For” votes and Lilian Y. Zhou receiving 41.9 million.
Auditor ratification (Proposal 2): BDO USA, P.C. was confirmed as independent auditor for fiscal 2025 with 44,463,071 “For” votes (≈99%), only 273,085 “Against,” and 10,537 abstentions.
Say-on-Pay advisory vote (Proposal 3): Compensation of named executive officers was approved on a non-binding basis, receiving 41,130,690 “For” votes (≈97.5%), 1,049,897 “Against,” 24,667 abstentions, and 2,541,439 broker non-votes.
No other matters were brought before the meeting, and no substantive changes to corporate strategy or financial guidance were disclosed.